EMEA-001207-PIP03-20

Table of contents

Key facts

Invented name
Gazyvaro
Active substance
Obinutuzumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0512/2020
PIP number
EMEA-001207-PIP03-20
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of glomerulonephritis and nephrotic syndrome
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration GmbH

E-mail: info.paediatrics@roche.com
Tel. +41 616879411

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating